Immunosuppressive drug-induced diabetes

Area of Science:

• Nephrology
• Endocrinology
• Immunology

Background:

• Post-transplant diabetes mellitus (PTDM) is a growing concern in organ transplant recipients due to increased survival rates.
• Immunosuppressive drugs (ISDs) are primary culprits, with corticosteroids exacerbating insulin resistance and calcineurin inhibitors directly harming pancreatic beta-cells.

Purpose of the Study:

• To review the mechanisms by which various immunosuppressive agents contribute to PTDM.
• To discuss current strategies for PTDM prevention and management in transplant patients.

Main Methods:

• Review of existing literature on PTDM pathogenesis and clinical outcomes associated with different immunosuppressive drugs.
• Analysis of clinical evidence comparing tacrolimus and cyclosporine in PTDM development.
• Evaluation of treatment options for established PTDM.

Main Results:

• Corticosteroids impair insulin sensitivity, while calcineurin inhibitors (e.g., tacrolimus) can cause beta-cell toxicity and reduced insulin secretion.
• Tacrolimus is associated with a higher incidence of PTDM compared to cyclosporine.
• Reducing corticosteroid use and optimizing tacrolimus levels are key preventive strategies; switching to cyclosporine may improve glucose control.

Conclusions:

• Tailoring immunosuppressive regimens based on PTDM risk factors is crucial.
• Further research is needed to confirm the safety and efficacy of certain PTDM treatments, such as thiazolidinediones and incretin-based therapies.